Encision Inc., a medical device company specializing in surgical instruments, reported a decline in financial performance for the quarter and six months ended September 30, 2025. The company generated total revenue of $1.53 million for the quarter, down 13% from $1.76 million in the same period last year. For the six-month period, revenue decreased by 8% to $3.13 million compared to $3.39 million in the prior year. The decline in revenue was attributed primarily to reduced sales of disposable products, indicating a decrease in the number of procedures performed.
The company's net loss for the quarter was $267,833, compared to a loss of $170,262 in the same quarter of the previous year. For the six months, the net loss increased to $308,966 from $148,222. The increase in losses was largely due to lower sales volume and an unfavorable change in product mix, with a higher proportion of lower-margin products sold. Gross profit for the quarter was $697,333, representing a 16% decrease from $828,482 in the prior year, while gross profit for the six months was $1.58 million, down 11% from $1.77 million.
Encision's operational metrics showed a decrease in product revenue, with net product revenue for the quarter at $1.48 million, down 10% year-over-year. Service revenue also fell significantly, from $101,568 to $46,248, due to a temporary suspension of services under a Master Services Agreement with Vicarious Surgical Inc. The company reported a working capital increase to $1.38 million as of September 30, 2025, up from $1.04 million at the end of the previous fiscal year, primarily due to a $500,000 capital raise from a private placement of common stock.
In terms of strategic developments, Encision has focused on expanding its market presence through the promotion of its patented Active Electrode Monitoring (AEM) technology, which aims to enhance patient safety during minimally invasive surgeries. The company is also investing in research and development to improve its product offerings and is exploring international markets for potential growth. However, the company faces challenges, including the need for additional capital to sustain operations, as it reported an accumulated deficit of $23.07 million as of September 30, 2025.
Looking ahead, Encision's management expressed concerns about the company's liquidity, indicating that current cash resources may not be sufficient to support operations beyond the next 12 months. The company plans to pursue additional equity or debt financing to address its capital needs. Despite the challenges, Encision aims to increase its market share and improve sales efficiency through enhanced marketing strategies and product development initiatives.
About ENCISION INC
Encision Inc. develops and markets innovative electrosurgical instruments with Active Electrode Monitoring (AEM) technology that enhances patient safety by preventing stray electrical burns during minimally invasive surgery. Its product line includes shielded, monitored laparoscopic instruments and monitors, targeting the laparoscopic monopolar electrosurgery market. The company focuses on education, expanding distribution, and international growth to establish AEM as a standard of care in surgical procedures.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.